New antibiotic cocktail takes on superbugs in phase 3 trial

NCT ID NCT05905055

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two new antibiotic combinations (cefepime/nacubactam and aztreonam/nacubactam) against the best available treatments for adults with serious infections like urinary tract infections, pneumonia, and abdominal infections caused by carbapenem-resistant bacteria. The trial enrolled 126 participants and compared how well each treatment worked and how safe it was. The goal was to see if these new combinations could successfully treat these hard-to-kill infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Cefepime/nacubactam and aztreonam/nacubactam (antibiotic combinations)

What this could lead to

If successful, this could provide new treatment options for serious infections that are resistant to many current antibiotics.

What could go wrong

This is a relatively small phase 3 trial (126 participants) and results may not apply to all patients. The new drug combinations may not work better than existing therapies and could have side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COMPLICATED INTRA-ABDOMINAL INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute pyelonephritis bacterial urinary tract infection infectious peritonitis nosocomial infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Meiji Research Site

    Changsha, China

  • Meiji Research Site

    Chongqing, China

  • Meiji Research Site

    Fuyang, China

  • Meiji Research Site

    Guangzhou, China

  • Meiji Research Site

    Hangzhou, China

  • Meiji Research Site

    Hefei, China

  • Meiji Research Site

    Nanjing, China

  • Meiji Research Site

    Nanning, China

  • Meiji Research Site

    Quanzhou, China

  • Meiji Research Site

    Shanghai, China

  • Meiji Research Site

    Shenzhen, China

  • Meiji Research Site

    Shijiazhuang, China

  • Meiji Research Site

    Wuxi, China

  • Meiji Research Site

    Xuzhou, China

  • Meiji Research Site

    Zagreb, Croatia

  • Meiji Research Site

    Kyjov, Czechia

  • Meiji Research Site

    Limoges, France

  • Meiji Research Site

    Nîmes, France

  • Meiji Research Site

    Paris, France

  • Meiji Research Site

    Strasbourg, France

  • Meiji Research Site

    Kutaisi, Georgia

  • Meiji Research Site

    Tbilisi, Georgia

  • Meiji Research Site

    Zestaponi, Georgia

  • Meiji Research Site

    Athens, Greece

  • Meiji Research Site

    Be’er Ya‘aqov, Israel

  • Meiji Research Site

    Ramat Gan, Israel

  • Meiji Research Site

    Tel Aviv, Israel

  • Meiji Research Site

    Nankoku, Kochi, Japan

  • Meiji Research Site

    Hiroshima, Japan

  • Meiji Research Site

    Kanazawa, Japan

  • Meiji Research Site

    Nagasaki, Japan

  • Meiji Research Site

    Nankoku, Japan

  • Meiji Research Site

    Ōta-ku, Japan

  • Meiji Research Site

    Shinjuku-ku, Japan

  • Meiji Research Site

    Toyoake, Japan

  • Meiji Research Site

    Daugavpils, Latvia

  • Meiji Research Site

    Liepāja, Latvia

  • Meiji Research Site

    Riga, Latvia

  • Meiji Research Site

    Valmiera, Latvia

  • Meiji Research Site

    Nitra, Slovakia

  • Meiji Research Site

    Svidník, Slovakia

  • Meiji Research Site

    Córdoba, Spain

  • Meiji Research Site

    Madrid, Spain

  • Meiji Research Site

    Kaohsiung City, Taiwan

  • Meiji Research Site

    Taichung, Taiwan

  • Meiji Research Site

    Taipei, Taiwan

  • Meiji Research Site

    Bangkok, Thailand

  • Meiji Research Site

    Chiang Mai, Thailand

  • Meiji Research Site

    Khon Kaen, Thailand

  • Meiji Research Site

    Ankara, Turkey (Türkiye)

  • Meiji Research Site

    Eskişehir, Turkey (Türkiye)

  • Meiji Research Site

    Istanbul, Turkey (Türkiye)

  • Meiji Research Site

    İzmit, Turkey (Türkiye)

  • Meiji Research Site

    Trabzon, Turkey (Türkiye)